Aflac Cancer and Blood Disorders Center of Children’s at Egleston
The Aflac Cancer Center is pediatric cancer center that provides advanced medical treatment, through clinical trials, and offers family-centered care and a child-friendly environment. Aflac Cancer Center physicians are involved in national clinical trials and collaborative studies of the Children’s Oncology Group (COG), the National Cancer Institute, the National Institutes of Health and the Pediatric Blood and Marrow Transplant Consortium. The Aflac Cancer Center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. Children’s Healthcare of Atlanta is accredited by the American College of Radiology (ACR). Located in Atlanta, Georgia, the Aflac Cancer Center has three locations: Children’s at Egleston, Children's at Hughes Spalding and Children’s at Scottish Rite. Each location features the following services: full range of pediatric infusional and apheresis services; onsite, innovative diagnostics, cell processing laboratory and oncology pharmacy; a 20-plus-member family support team—including child life specialists, social workers, chaplains, teachers, psychologists and financial coordinators—that attends to the patient’s and family’s emotional, physical and financial well-being, as well as help the family identify and use all available resources during this difficult time.
Treatment Sites in Georgia
Clinical Trials in Georgia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator:
Sindy Midoro
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type: Hematopoietic Malignancies, Solid Tumor
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type: Leukemia
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type: Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type: Germ Cell Tumor, Testicular Cancer
An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Cancer Type: Adrenal Cancer, Neuroblastoma
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type: Hematopoietic Malignancies, Solid Tumor
Childhood Cancer Survivor Study
Cancer Type: Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
Study Coordinator:
Sindy Midoro
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Cancer Type: Hodgkin Lymphoma
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma
Cancer Type: Neuroblastoma
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Cancer Type: Sarcoma
Nab-paclitaxel followed by Gemcitabine Hydrochloride in Treating Pediatric Participants with Newly-Diagnostic, Relapsed or Refractory Solid Tumors
Cancer Type: Solid Tumor
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)
Neuroblastoma Biology Study
Cancer Type: Neuroblastoma
Optune Delivered Electric Field Therapy in Treating Children with Recurrent, Progressive, or Refractory High-Grade Glioma or Supratentorial Ependymoma
Cancer Type: Brain & Spinal Cord Tumor
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Cancer Type: Brain & Spinal Cord Tumor
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Cancer Type: Brain & Spinal Cord Tumor
Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type: Brain Tumor
Study Coordinator:
Sindy Midoro
Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type: Neuroblastoma
Study Coordinator:
Sindy Midoro
Rifaximin in Preventing Infections in Participants with Blood Cancer Undergoing Hematopoietic Stem Cell Transplantation
Cancer Type: Hematopoietic Malignancies
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type: Sarcoma, Solid Tumor
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Cancer Type: Solid Tumor
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Embryonal Tumors
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Neuroblastoma, Neurologocal Tumor
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia
Cancer Type: Leukemia
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Cancer Type: Leukemia
Study of Key Late-Occurring Complications in Childhood Cancer Survivors
Cancer Type: Multiple Primaries
Study Coordinator:
Sindy Midoro
Study of Long-Term Follow-Up in Patients Who Have Participated in Children's Oncology Group Studies
Cancer Type: Multiple Primaries
Study Coordinator:
Sindy Midoro
Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer
Study Coordinator:
Sindy Midoro
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Cancer Type: Leukemia
WP1066 for the Treatment of Recurrent or Refractory and Progressive Malignant Brain Tumors
Cancer Type: Brain & Spinal Cord Tumor
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please
contact us.